{
    "eid": "2-s2.0-85119877462",
    "title": "Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers",
    "cover-date": "2022-04-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Virology",
            "@code": "2406",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "COVID-19",
        "immunogenicity",
        "inactivated vaccine",
        "nucleocapsid protein",
        "RBD",
        "safety",
        "spike protein"
    ],
    "authors": [
        "Saovanee Benjamanukul",
        "Sasiwimon Traiyan",
        "Ritthideach Yorsaeng",
        "Preeyaporn Vichaiwattana",
        "Natthinee Sudhinaraset",
        "Nasamon Wanlapakorn",
        "Yong Poovorawan"
    ],
    "citedby-count": 18,
    "ref-count": 36,
    "ref-list": [
        "High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2",
        "The impact of the COVID-19 pandemic on medical education",
        "Emotional, behavioral, and psychological impact of the COVID-19 pandemic",
        "Observed impacts of the COVID-19 pandemic on global trade",
        "Viral targets for vaccines against COVID-19",
        "Current status of COVID-19 vaccine development: focusing on antigen design and clinical trials on later stages",
        "Approaches and challenges in SARS-CoV-2 vaccine development",
        "Overview of approved and upcoming vaccines for SARS-CoV-2: a living review",
        "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",
        "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",
        "Development of an inactivated vaccine candidate for SARS-CoV-2",
        "Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies",
        "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",
        "Details of Medicinal Product",
        "Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients",
        "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials",
        "ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets",
        "Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273",
        "Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial",
        "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine",
        "Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine",
        "Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status",
        "Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers",
        "Correlates of protection against SARS-CoV-2 in rhesus macaques",
        "Antibody status and incidence of SARS-CoV-2 infection in health care workers",
        "Evidence for antibody as a protective correlate for COVID-19 vaccines",
        "Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers",
        "Antibody response to SARS-CoV-2 infection in humans: a systematic review",
        "A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients",
        "Longitudinal assessment of anti-SARS-CoV-2 immune responses for six months based on the clinical severity of COVID-19",
        "Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection",
        "Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection"
    ],
    "affiliation": [
        {
            "affiliation-city": "Samut Sakhon",
            "@id": "125901632",
            "affilname": "Banphaeo General Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/125901632",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "127148398",
            "affilname": "FRS(T)",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127148398",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Center of Excellence in Clinical Virology",
        "King Chulalongkorn Memorial Hospital",
        "Chulalongkorn University",
        "National Research Council of Thailand"
    ]
}